Markets Edge

ReadingAnthropic's valuation floor is now $900B+. Every Series C AI company in the market just had their internal financing model rewritten. The scarcity of world-class reasoning models is priced into capital allocation now.

ReadingOne Equity's Fund IX close signals continued institutional appetite for mid-market buyout activity. The firm's ability to raise at size in this market indicates strong portfolio performance and LP confidence in their model.

ReadingObesity biotech valuations are now priced for outcome, not promise. Kailera's record IPO size signals strong institutional appetite for well-positioned obesity therapeutics at commercial scale. The next obesity IPO prices at or above this waterline.

ReadingSeaport's $201M IPO size reflects mature biotech fundamentals in a narrower category. Neuropsychiatric therapeutics attracted institutional capital but at a more conservative valuation than obesity plays. The category discipline is intact.

ReadingConnecticut's 14% return is a signal of aggressive equity positioning that paid. Large pension allocators will compare their own calendar performance against this benchmark. Underperformers begin rebalancing or staff reviews within 30 days.

ReadingSynchronized buybacks across BBVA, ING, Builders FirstSource, and Luckin Coffee signal that capital structures are optimizing for shareholder returns over growth investment. Earnings strength is being funneled to buyback rather than reinvestment. This is the pattern of a mid-cycle market reassessing growth narratives.

ReadingInfleqtion's SPAC approach signals quantum startups are still raising at founder-friendly terms, but the $160B TAM narrative is doing the heavy lifting. Expect the SPAC merge to value the company well below that market size. The gap between claimed opportunity and actual valuation is where sophistication shows.